Clinical Trials

75 enrolled

Dermatologic

Melanoma

NCT04071236 2026-03-19

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

90 enrolled

Lymphatic Metastasis, Prostatic Neoplasms

NCT04345913 2026-03-19

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

24 enrolled 24 charts

Breast

Triple Negative Breast Neoplasms

NCT05896839 2026-03-19

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

16 enrolled

Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT07012031 2026-03-19

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

37 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07437963 2026-03-19

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

76 enrolled

Neuroblastoma, Ganglioneuroblastoma

NCT01038778 2026-03-18

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

47 enrolled 15 charts

Carcinoma, Renal Cell

NCT03604978 2026-03-18

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

38 enrolled

Meningioma

NCT03854474 2026-03-18

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

30 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04172532 2026-03-18

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

92 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04557956 2026-03-18

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

16 enrolled

Dermatologic

Melanoma

NCT05099003 2026-03-18

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

132 enrolled

Glioma

NCT05286801 2026-03-18

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

86 enrolled

Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

NCT05432804 2026-03-18

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Phase 1/2 Suspended

97 enrolled

Glioblastoma

NCT05691491 2026-03-18

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

58 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT07069699 2026-03-18

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

50 enrolled

Lymphoid

Burkitt Lymphoma

NCT06287775 2026-03-12

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

45 enrolled

Lung Neoplasms

NCT01116648 2026-03-05

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT03317392 2026-02-19

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

145 enrolled

Prostatic Neoplasms

NCT04541017 2025-10-16

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Phase 1/2 Terminated

8 enrolled 8 charts

Lymphoid

Mycosis Fungoides, Sezary Syndrome

NCT02079740 2025-09-30

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

96 enrolled 30 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT03831932 2025-09-19

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

22 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Phase 1/2 Withdrawn

GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma

NCT01902173 2025-01-14

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

DermatologicOther hematologic neoplasm

27 enrolled 16 charts

Melanoma, Neoplasm Metastasis, Hematologic Neoplasms

NCT04216316 2024-07-03

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

12 enrolled

Lung Neoplasms

NCT00662506 2023-06-06

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

46 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT00416455 2019-07-23

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

384 enrolled 23 charts

Gynecologic

Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT00095940 2014-05-23

Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors

52 enrolled 17 charts